Value-Based Pricing

What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.

OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on 5th May.

A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.

Rachel Baker of Glasgow Caledonian University and Koonal Shah of OHE discussed societal viewpoints regarding end of life treatments at a recent seminar.

“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.

This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?

Pages

Subscribe to RSS - Value-Based Pricing